Prabhudas Lilladher's research report on Divis Laboratories
Divi’s Laboratories (DIVI) Q2FY26 EBITDA was a beat; 7% above our estimates led by higher CS revenues. We expect margins to improve, led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP’s and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. Our FY26E/FY27E EPS estimates broadly remain unchanged.
Outlook
We expect 20% EBITDA CAGR and 19% PAT CAGR over FY25-28E. At CMP, stock is trading at 53x Sept2027E EPS. We Maintain our ‘Accumulate’ rating with revised TP of Rs7,050/share, valuing at 55x Sept 2027E EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
